secwatch.observer — SEC 8-K summary
======================================

Issuer:     Amneal Pharmaceuticals, Inc. (AMRX)
CIK:        0001723128
Form:       8-K
Filed at:   2023-01-10T23:59:59+00:00
Accession:  0001193125-23-005141
Event type: other
Sentiment:  neutral
Materiality: 0.25
Item codes: 2.02, 7.01
LLM model:  deepseek-v4-flash:cloud@v2

Amneal reaffirms FY2022 guidance: revenue $2.15-2.25B, adj. EBITDA $500-520M
----------------------------------------------------------------------------

- Reaffirmed FY2022 net revenue guidance of $2.15B-$2.25B; no change from Nov 4, 2022.
- Adjusted EBITDA forecast unchanged at $500M-$520M; adjusted diluted EPS $0.65-$0.70.
- Operating cash flow guidance $200M-$225M; capex $65M-$75M; diluted shares ~305M.
- Guidance includes 100% of AvKARE EBITDA; accounts for 35% non-controlling interest.
- Opana ER antitrust litigation cash payments of ~$131M excluded from operating cash flow guidance.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1723128/000119312523005141/0001193125-23-005141-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1723128/000119312523005141/d416892d8k.htm
  HTML page:      https://secwatch.observer/filing/0001193125-23-005141

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer